PART I . Overview We are a biotechnology company committed to discovering and developing product candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair. Our current strategic focus is ophthalmology, where Wnt signaling plays a central role in retinal vascular integrity, barrier function, and tissue maintenance. We are located in South San Francisco, California. Our mission is to transform the treatment of serious ophthalmic disease by fully exploiting the Wnt pa...
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001193125-26-119818 | EDGAR | 89K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-047712 | EDGAR | — |
| 2024-04-10 | 2023-12-31 | 0000950170-24-043399 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0000950170-23-011118 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0000950170-22-004787 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001104659-21-044518 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0001193125-25-272422 | EDGAR | 62K words |
| 2025-08-08 | 2025-06-30 | 0000950170-25-105847 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0000950170-25-068046 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122318 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095443 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055706 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061150 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0000950170-23-040648 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0000950170-23-020618 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-025096 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016889 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0000950170-22-009343 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-23 | 0001193125-26-119757 | EDGAR | 3K words |
| 2026-01-30 | 0001193125-26-031798 | EDGAR | — |
| 2025-11-07 | 0001193125-25-272363 | EDGAR | — |
| 2025-10-17 | 0001193125-25-242518 | EDGAR | — |
| 2025-08-29 | 0000950170-25-112253 | EDGAR | — |
| 2025-08-08 | 0000950170-25-105839 | EDGAR | — |
| 2025-05-15 | 0000950170-25-072696 | EDGAR | — |
| 2025-05-09 | 0000950170-25-068011 | EDGAR | — |
| 2025-03-31 | 0000950170-25-047702 | EDGAR | — |
| 2025-03-28 | 0000950170-25-046769 | EDGAR | — |
106 total filings indexed. 78 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001824893 |
| Ticker | SRZN |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.surrozen.com |
| Listed | 2021-08-12 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report